Decreased Fracture Rate When Adding Bone Protecting Agents to Radium-223: PEACE III- Bertrand F. Tombal
Bertrand F. Tombal, MD, PhD, Professor and Chair, Université Catholique de Louvain, Brussels, Belgium
Thomas Keane, MBBCh, FRCSI, FACS , Professor and Chairman of the Department of Urology at the Medical University of South Carolina, Charleston, South Carolina. He holds a U.S. patent for BNCT in prostate cancer and sphingolipid derivatives and their use.
Decreased Fracture Rate by Mandating Bone-protecting Agents in the EORTC 1333/PEACE III Trial
NCT02194842: A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.